Steven J. Borst
President, Chief Executive Officer, and Chairman of the Board of Directors

Mr. Borst serves as President, Chief Executive Officer, and Chairman of Q Therapeutics, Inc. He has led the financial and corporate development activities of the Company since its inception. Mr. Borst has over 30 years of company formation and operating experience in the life sciences sector with a specific focus on biotechnology and medical devices since 2001. He has served in senior executive positions and business development roles including CEO of ACT/PC (NASDAQ:MCK), and VP Business Development of American WholeHealth (NASDAQ:HWAY). Mr. Borst has worked as a venture capital investor, partnering in early-stage equity investments in Cytyc (NASDAQ:HOLX), Sunrise Senior Living (formerly Sunrise Assisted Living – SNRZ), and US Servis (NASDAQ:MCK). He holds a Bachelor of Science (Industrial Engineering and Operations Research) from the University of Michigan and a Master of Management degree from Northwestern University’s J.L. Kellogg Graduate School of Management.  

Mahendra Rao, MD, Ph.D.
Scientific Co-founder, Chief Strategy Officer and Chairman of the Scientific Advisory Board

Dr. Rao is the scientific founder of Q and world renowned for his work with neural stem cells. Most recently, he served as Director of the Intramural Center for Regenerative Medicine at the National Institutes of Health (NIH). He also held joint research appointments at the at the National Institute of Neurological Disorders and Stroke (NINDS) and the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) from 2011-March 2014. Previously, Dr. Rao was Vice President of Stem Cell Research at Life Technologies, Inc. (now Thermo Fisher Scientific, NYSE: TMO) from 2006-2011; Stem Cell Section Chief at the Laboratory of Neurosciences at the NIH National Institute of Aging from 2001-2005; and at the University of Utah School of Medicine from 1994-2001, where he became Associate Professor with tenure in Neurobiology and Anatomy.

David A. Green, CPA
Chief Financial Officer

Mr. Green serves as the Chief Financial Officer of Q Therapeutics, bringing more than 20 years of financial management and life sciences investment banking experience to the position. He has served as the Chief Financial Officer for a variety of public and private companies including Specialized Health Products, a medical device firm where he managed financial operations, investor relations and M&A activities. SHPI was acquired by C.R. Bard (NYSE:BCR) during his tenure. Additionally, Mr. Green served as Vice President, Chief Financial Officer and Treasurer of SJW Corp. [NYSE: SJW] an investor owned utility serving Silicon Valley and parts of Texas. Earlier in his career, Mr. Green was a Managing Director of Duff & Phelps, LLC, an investment banking and financial advisory firm, where he led the life sciences investment banking practice in San Francisco, California. Prior to joining Duff & Phelps, Mr. Green was a Director in Ernst & Young’s Center for Strategic Transactions where he advised Silicon Valley technology and life science companies on transaction strategies for accelerating growth. Mr. Green is a graduate of the State University of New York, majoring in chemistry with concentrations in biology and mathematics. He has an MBA degree (finance) from the University of Rochester. He is a registered CPA in the State of Illinois.

James T. Campanelli, Ph.D. 
Vice President, Research & Development

Dr. Campanelli serves as Vice President of Research and Development at Q Therapeutics. He received a B.S., M.S. and Ph.D. in biological sciences, all from Stanford University. His Ph.D. research focused on the cellular and molecular bases of neuromuscular synapse formation. Following a Howard Hughes Medical Institute postdoctoral fellowship at Stanford, Dr. Campanelli was an Assistant Professor in the Department of Biochemistry at the University of Illinois Urbana-Champaign, where his lab continued to investigate motor neuron-muscle interactions involved in the development of mature neuromuscular synapses, and then a scientist at Amersham Biosciences/GE Healthcare where he worked to develop high content assays for monocyte chemotactic and invasive behavior. At Q Therapeutics, since 2004, he has led all R&D and IND enabling activities related to the Company’s proprietary, patented Q-Cells® technology, including the successful submission of Q’s first IND for the ALS indication. He also manages interactions with external collaborators working to develop Q-Cells® for additional indications (including Transverse Myelitis, Multiple Sclerosis, Spinal Cord Injury, Parkinson’s, and Huntington’s), and to develop second and third generation cellular therapeutics.